Four partners have gotten together in the hopes of developing technology to replace traditional glucometers--and maybe even manage insulin delivery with smartphone-based systems. Wearables specialist Gentag and the Mayo Clinic are expanding upon their ongoing collaboration and adding into the mix a pair of existing partners: sensor maker NovioSense and the Fraunhofer Institute for Microelectronic Circuits and Systems (IMS).
GlaxoSmithKline is the first pharma company to get behind the U.K.'s forthcoming Francis Crick Institute, signing on to lend its minds and molecules to an open R&D effort.
Sanofi has widened its R&D net, recruiting 7 of the U.S.'s most-respected research institutions in hopes of ferreting out some new ideas in early-stage drug development.
The National Basketball Association and GE Healthcare have signed a multiyear deal to work together to advance the prevention, diagnosis and treatment of musculoskeletal conditions among NBA players.
Billionaire entrepreneur Patrick Soon-Shiong further complicated his sprawling biotech empire with another joint venture, teaming up with frequent collaborator Sorrento Therapeutics to launch a new company focused on oncology.
Swedish contractor Recipharm has deepened its ties with partner Pharmanest, taking up a 25% stake in the biotech as the two collaborate on a pain drug.
Sanofi has re-upped with its partners at Medicines for Malaria Venture in hopes of developing a single-dose treatment for the infectious disease, advancing a pair of candidates through mid-stage development.
Long-stealthy inexpensive diagnostics provider Theranos has announced its first deal to become a diagnostics provider for a major health insurer: Capital BlueCross of Pennsylvania, which has about 1 million members. Last week, the company divulged that the FDA had cleared one of its tests for the first time.
On Tuesday, the U.S. government placed a large new order for Bavarian Nordic's smallpox vaccine while the company continues work to improve its formulation to offer more stockpiling flexibility.
South Korea-based Samsung Bioepis is ready to head to regulators with a biosimilar of AbbVie's Humira (adalimumab) after successfully completing Phase III trials on its candidate now dubbed SB5. The company says SB5 met its primary endpoint and showed equivalence to the original version in patients with moderate to severe rheumatoid arthritis who did not respond to methotrexate therapy.